MTOR and neoplasm: The advent of molecular testing has helped identify subset of tumors with potentially targetable mutations, not least mutations in BRAF, mTOR, and ERBB2. Even though partial responses have been noted, exceedingly few patients survive once the tumor spreads to distant sites[13,14].